CD274 and acute myeloid leukemia: Immunotherapy of AML expressing mtNPM1 with anti-CD33 or CD123 strategies [55–57], anti-PD1 or PD-L1 antibodies-based combinations [58, 59], or anti-CD123 directed chimeric antigen receptor (CAR-T) cells are also being investigated [60].